Plasma Derived Medicine Market
Report ID: SQMIG35I2877
Report ID: SQMIG35I2877
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2877 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
178
|Figures:
79
Global Plasma Derived Medicine Market size was valued at USD 40.3 Billion in 2024 and is poised to grow from USD 43.16 Billion in 2025 to USD 74.72 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).
Therapeutic proteins derived from human plasma, such as immunoglobulins (Ig), coagulation factors and albumin, packaged as life-saving biologics are considered to be the basis of the plasma-derived medicines market. The reason why plasma-derived medicines are so crucial is that they are able to treat rare bleeding disorders, immune deficiencies and critical-care situations where traditional pharmaceuticals fail to provide effective relief for the patient. The plasma-derived medicines market originated in the early 1970s when IVIG was first introduced. The expansion of the plasma-derived medicines market occurred after 1990 due to the introduction of recombinant technologies that demonstrated the safe use of plasma. The current plasma-derived medicines market is considered to be a $30 billion industry with multiple contributing factors such as increases in hemophilia diagnosis, the Baby Boomer generation requiring immune system support due to age, and increased global awareness of plasma-derived therapies. Moving forward, the primary means of plasma derived medicine market growth will be from the increasing demand for hemostatic and immunomodulatory agents as a result of evidence of their efficacy in clinical use.
As the medical community learns that patients with severe hemophilia A and hemophilia B have significantly lower infection rates and have longer half-lives of their plasma-derived clotting factors compared to recombinant-based clotting factors, hospitals will continue to purchase larger percentages of these products. This trend of increasing purchases results in growing procurement volumes for hospitals, thus creating a self-perpetuating cycle. Further, new indications such as the use of convalescent plasma therapy during viral pandemics and the use of albumin in hospitals for critical-care nutrition will open new revenue sources for manufactures of plasma-derived medicines. This convergence of therapeutic validation, regulatory incentives, and rising procurement budgets translates into a projected compound growth rate of eight percent through 2035.
How is AI Accelerating Product Development In The Plasma-derived Medicines Market?
The advancements in artificial intelligence are revolutionizing the development of medicines that are created from plasma. Through the advancement of technologies in artificial intelligence, the identification of targets for therapy can be completed more quickly and effectively, protein engineering can be performed with optimized results, and clinical trial design can be improved with the use of automation. For example, machine learning can analyze large immunoglobulin datasets and accurately predict the stability of a given antibody candidate which will significantly decrease the time needed for laboratory experiments. In addition, natural language processing is used to analyze various regulatory documents, which provides valuable insights to the business on how to more quickly navigate the approval process. The use of cloud-based simulation platforms also allows for virtual testing of antibody purification methods, which minimizes material waste through development cycles.
The use of these technologies allows manufacturers to develop medications for the growing market demand for the treatment of chronic illnesses while adhering to industry safety standards. The demand for these technologies is anticipated to increase as efficiencies created by artificial intelligence will reduce the time to bring a new product to market and ultimately support a broader category of products in the marketplace (an industry that is estimated to be a value of $10's of billions). In April 2026, a leading plasma derived therapy company launched an antibody purification platform that enhances the purification process through the integration of real-time analytics and predictive modeling. This technology enables the manufacturer to select candidates from an accelerated timeline and carry out laboratory trials with a shorter timeline for the delivery of the medication to their patients.
Market snapshot - (2026-2033)
Global Market Size
USD 40.3 Billion
Largest Segment
Albumin
Fastest Growth
Hyperimmune Globulins
Growth Rate
7.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global plasma derived medicine market is segmented by product type, application, route of administration, end user, patient group, distribution channel and region. Based on product type, the market is segmented into Immunoglobulins, Coagulation Factors, Albumin, Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins and Others. Based on application, the market is segmented into Immunodeficiency Disorders, Hemophilia, Neurological Disorders, Critical Care & Trauma, Infectious Diseases and Others. Based on route of administration, the market is segmented into Intravenous, Subcutaneous and Intramuscular. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Infusion Centers and Home Healthcare Settings. Based on patient group, the market is segmented into Pediatric, Adult and Geriatric. Based on distribution channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
As per plasma derived medicine market forecast, Immunoglobulins are the dominant segment, as they are the base therapeutic class for many different types of immune deficiency and infectious disease treatment. Their broad clinical acceptance leads to ongoing demand by both hospital and specialty clinics, while their long standing manufacturing methods provide assurance of availability. Clinicians depend on their proven therapeutic benefits, which reinforces purchasing trends and encourages manufacturers to focus on continued scale-up efforts and additional innovative product development, ultimately providing sustained market dominance for both the products and for the outcomes of the patients treated with these products.
As pathogen-specific therapy becomes more mainstream, hyperimmune globulins are experiencing the greatest momentum for growth (i.e., expanded use). In addition, new regulatory support has improved the collection of plasma, which has led to enhanced product introduction timelines; this will expand the overall use of these products in both prophylactic and therapeutic protocols. The rapid acceptance of hyperimmune globulins will create an expanded market for these products, new revenue potential for manufacturers, and increased research and development (R&D) dollars being allocated toward the development of additional hyperimmune globulin products.
The greatest section of the Hemophilia segment continues to lead, as coagulation factor concentrates are still the gold standard for treating patients with bleeding disorders. The need for consistent supply in hospital pharmacies and specialty clinics continues to be strong due to the chronicity of hemophilia, which results in an ongoing need for repeat prescriptions. Advancements in recombinant technology will continue to build clinician confidence in the use of coagulation factor concentrates. Additionally, reimbursement policies focusing on these life-saving products will continue to propel manufacturers to invest heavily in efforts for ongoing supply assurance and product improvement, further solidifying the market dominance of coagulation factor concentrates within the global market for therapeutic agents.
As per plasma derived medicine market analysis, neurologic disorders are becoming the primary area of high-growth as plasma-derived albumin and alpha-1-proteinase inhibitors are being used in neuroprotective protocols. The results from ongoing clinical studies and the growing body of evidence supporting their efficacy in neurologic disorders have led to increased adoption of these therapies among clinicians and a continued increase in supportive regulatory pathways. This growth will create new market opportunities and enable funding for the development of innovative formulations.
To get detailed segments analysis, Request a Free Sample Report
North America is the leading region in the global plasma derived medicines because of its advanced infrastructure, solid research environment and favourable regulations that expedite the development and launch of products into the marketplace. The US has a large concentration of state-of-the-art plasma collection centres and biotechnology companies that convert scientific advances into commercially viable therapeutic products. The extensive reimbursement systems and integrated payer systems provide significant access to these products. The highly skilled clinical workforce ensures that product safety and efficacy are at the highest levels. Collaborative partnerships between government, academia and industry provide acceleration within the innovation pipeline and position this part of the world as the primary hub for plasma derived therapeutics. Additionally, the presence of large volume manufacturing facilities and an established supply chain reduce time to market; proactive government incentives further encourage continued investment in plasma technology. Overall, the scientific depth, availability of capital and patient centric policies provide a synergistic environment to sustain North America's predominance in the plasma derived medicines market.
The United States Plasma Derived Medicine market is assisted by the widespread availability of the thousands of plasma donation centers that provide high-quality plasma for the purpose of fractionation. The presence of established biotech companies and leading research hospitals continues to drive new development in the field of plasma-based therapies. Clearly defined reimbursement pathways make it easy for both large hospitals and specialized clinics to use the various Plasma Derived Medicine products. Well-established collaborations between public and private sector entities continue to improve the potential for clinical studies of new Plasma Derived Medicine products developed from advances in scientific research to be translated rapidly to patients who need them.
The development of the Canadian Plasma Derived Medicine market is supported by a culture of donating Plasma voluntarily to the National Health Authorities, as well as a strong commitment from Canadian National Health Authorities to encourage Canadians to donate Plasma. Regional collection networks for the collection of Plasma feed into fractionation facilities to continuously provide Plasma-derived products. Regulatory processes that align with international standards ensure that new Plasma Derived Medicine therapies will have smooth access to the Canadian market, and funding for research programs provides for collaboration between universities and industry. Canada has an integrated payer system that allows for easy access to products for all patients, reinforcing the importance of Canada within the global Plasma ecosystem as an on-going contributor.
Europe experiences rapid expansion of the plasma derived medicine market due to a confluence of regulatory cohesion, extensive clinical research infrastructure, and proactive public health policies. The European Medicines Agency provides a unified framework that streamlines product approval across member states, encouraging manufacturers to scale operations continent‑wide. Robust hospital networks and specialized treatment centers facilitate early adoption of plasma‑based therapies, while collaborative research consortia link academic institutions with biotech firms to accelerate innovation. Reimbursement models that balance cost‑effectiveness with patient access support sustainable market growth. Additionally, heightened awareness of rare and chronic disorders among policymakers drives investment in plasma‑derived solutions, positioning Europe as a vibrant hub for therapeutic development and distribution. Cross‑border collaborations are further reinforced by EU funding mechanisms that de‑risk early‑stage projects, allowing innovators to translate laboratory breakthroughs into clinically viable products. The emphasis on personalized medicine also aligns with plasma‑based approaches, fostering a supportive environment for continued market expansion.
Plasma Derived Medicine Market Germany benefits from a well‑established plasma collection network integrated with leading research hospitals and biotech clusters. The country's strong manufacturing capabilities enable efficient processing of plasma into high‑quality therapeutics. Close alignment with European regulatory standards accelerates product rollout, while public health initiatives prioritize plasma‑derived treatments for immunodeficiencies and rare diseases. Collaborative funding programs unite academia and industry, reinforcing Germany’s position as a central hub for plasma innovation.
Plasma Derived Medicine Market United Kingdom is emerging as a environment for plasma therapies, supported by a growing donor base and expanding clinical trial infrastructure. Government incentives encourage investment in plasma fractionation and advanced manufacturing, while leading academic centers drive translational research. The NHS framework facilitates reimbursement pathways, allowing quicker patient access. Partnerships between multinational firms and local biotech start‑ups foster a collaborative ecosystem that accelerates adoption of plasma‑derived solutions.
Plasma Derived Medicine Market France is witnessing the fastest growth in Europe, driven by strong governmental commitment to rare disease treatment and a robust bioscience sector. National health agencies prioritize reimbursement for plasma‑derived products, enhancing patient uptake. Research institutions excel in immunology and hematology, supplying a pipeline of innovative indications. Strategic alliances between French biotech firms and global manufacturers expand manufacturing capacity and accelerate market penetration across the continent.
Asia Pacific is strengthening its position in the plasma derived medicine market through accelerated investment in research infrastructure, supportive regulatory reforms, and a growing emphasis on advanced therapeutic solutions. Japan leads with a mature plasma collection system and pioneering work in plasma‑derived immunoglobulins, backed by government initiatives that streamline clinical development pathways. South Korea complements this momentum by fostering biotech start‑ups focused on novel plasma applications and by aligning its regulatory standards with international benchmarks, facilitating faster market entry. Regional collaborations across universities, hospitals, and industry accelerate knowledge transfer and product diversification. Rising awareness of chronic and rare diseases among healthcare providers and patients drives demand for high‑quality plasma therapeutics, while evolving reimbursement frameworks improve accessibility across the continent. Additionally, the region’s commitment to sustainable plasma sourcing ensures a reliable supply chain, reinforcing its competitive edge in the global marketplace.
Plasma Derived Medicine Market Japan boasts a comprehensive plasma donation framework complemented by cutting‑edge fractionation facilities that produce a broad spectrum of plasma‑derived therapeutics. Strong collaboration between government agencies, academic centers, and industry accelerates the translation of research into marketable products. Reimbursement policies are aligned to support patient access, while public awareness campaigns encourage donor participation. Continuous investment in bioprocessing technologies sustains Japan’s leadership in high‑quality globally recognized advanced plasma‑based treatments.
Plasma Derived Medicine Market South Korea is developing its plasma sector by nurturing biotech ventures that focus on plasma applications such as regenerative therapies and immunoglobulins. Governmental incentives streamline regulatory approval and provide funding for clinical trials, encouraging market entry. Collaboration between hospitals and research institutes creates a pipeline of clinical evidence supporting product adoption. An evolving reimbursement landscape enhances patient affordability, positioning South Korea as an emerging hub for advanced plasma‑derived solutions.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Demand for Immunotherapies
Advancements in Plasma Collection Technologies
Stringent Regulatory Approval Processes
High Production Costs and Complexity
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the plasma‑derived medicine market is shaped by intense rivalry among established manufacturers and fast‑moving biotech entrants, driving accelerated innovation and strategic consolidation. Companies are leveraging technology‑focused partnerships and high‑profile funding rounds to expand product pipelines, while recent M&A activity targets niche plasma‑derived assets to broaden therapeutic portfolios and secure market share. These dynamics intensify competition around novel plasma‑based therapies and cost‑effective manufacturing solutions.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global plasma‑derived medicine market is propelled primarily by the rising demand for immunotherapies that leverage plasma proteins to modulate immune responses, while a second strong engine comes from advances in plasma‑collection technologies that boost yields and product consistency. The immunoglobulins segment remains the market’s biggest contributor, reflecting its broad use across immune‑deficiency and infectious‑disease treatments. North America continues to dominate thanks to its mature collection network, robust reimbursement framework and extensive biotech ecosystem. However, the market’s pace is tempered by stringent regulatory approval processes that extend development timelines and increase costs, limiting faster expansion in the near term.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 40.3 Billion |
| Market size value in 2033 | USD 74.72 Billion |
| Growth Rate | 7.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Plasma Derived Medicine Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Plasma Derived Medicine Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Plasma Derived Medicine Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Plasma Derived Medicine Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Plasma Derived Medicine Market size was valued at USD 40.3 Billion in 2024 and is poised to grow from USD 43.16 Billion in 2025 to USD 74.72 Billion by 2033, growing at a CAGR of 7.1% during the forecast period (2026-2033).
The competitive landscape of the plasma‑derived medicine market is shaped by intense rivalry among established manufacturers and fast‑moving biotech entrants, driving accelerated innovation and strategic consolidation. Companies are leveraging technology‑focused partnerships and high‑profile funding rounds to expand product pipelines, while recent M&A activity targets niche plasma‑derived assets to broaden therapeutic portfolios and secure market share. These dynamics intensify competition around novel plasma‑based therapies and cost‑effective manufacturing solutions. 'CSL Limited', 'Grifols, S.A.', 'Takeda Pharmaceutical Company Limited', 'Kedrion Biopharma Inc.', 'Octapharma AG', 'China Biologic Products Holdings, Inc.', 'LFB S.A.', 'Biotest AG', 'GC Biopharma Corp.', 'Shanghai RAAS Blood Products Co., Ltd.', 'ADMA Biologics, Inc.', 'Intas Pharmaceuticals Ltd.', 'SK Plasma Co., Ltd.', 'Bharat Serums and Vaccines Limited', 'Kamada Ltd.', 'Hualan Biological Engineering Inc.', 'Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.', 'Sanquin Plasma Products B.V.', 'PlasmaGen Biosciences Pvt. Ltd.', 'Reliance Life Sciences Pvt. Ltd.'
Increasing demand for immunotherapies is driving significant expansion of plasma derived medicines as clinicians seek therapies that modulate immune responses with proven safety profiles. The ability of plasma proteins to provide passive immunity and regulate inflammation aligns with rising prevalence of autoimmune and infectious conditions, encouraging healthcare systems to incorporate these biologics into treatment protocols. Consequently, pharmaceutical developers are accelerating research pipelines and forging partnerships to meet clinical expectations, thereby reinforcing market momentum and fostering broader adoption across diverse therapeutic areas.
Personalized Immunotherapy Expansion: The market is witnessing a rapid shift toward patient‑specific plasma‑derived immunoglobulins and antibody cocktails that target unique disease signatures. Manufacturers are leveraging genomic profiling and advanced bioprocessing to create tailored therapies for oncology, autoimmune disorders, and infectious diseases. This move enhances clinical efficacy, drives physician adoption, and differentiates product portfolios, prompting firms to invest heavily in R&D collaborations with research institutes and to reconfigure manufacturing lines for flexible, small‑batch production and rapid market entry timelines globally soon.
Why does North America Dominate the Global Plasma Derived Medicine Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
